NCT01934023View on ClinicalTrials.gov

Effects of Varenicline on Plasticity in Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Schizophrenia
Interventions
DRUG

Varenicline

Champix (Varenicline) is an approved smoking cessation medication

DRUG

Placebo

Trial Locations (1)

M5T 1R8

Centre for Addiction and Mental Health, Toronto

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Centre for Addiction and Mental Health

OTHER

NCT01934023 - Effects of Varenicline on Plasticity in Schizophrenia | Biotech Hunter | Biotech Hunter